The bio-medical industry, unfortunately, leaves many extremely vulnerable when the standard of care is exhausted. Finding a way into clinical trials, for example, can be very difficult for an individual, especially if they’re already sick. The limited amounts of these clinical trials, combined with a reluctance of those who are ‘no option’ patients to participate in them, deepens the problem. As such, innovative, experimental, “n-of-1” options are required by millions of patients whom every year become ‘No-Option’.